[一季报]华东医药(000963):2024年第一季度报告（英文版）
|
时间：2024年06月12日 20:26:07 中财网 |
|
原标题: 华东医药:2024年第一季度报告（英文版）
Security code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2024-041
Huadong Medicine Co., Ltd.
First Quarterly Report 2024
The Company and all members of the Board of Directors hereby guarantee that the information presented
in this report is authentic, accurate and complete and free of any false records, misleading statements or material
omissions.Important Declaration:
1. The Board of Directors, Board of Supervisors, directors, supervisors and senior management of Huadong
Medicine Co., Ltd. (hereinafter referred to as the "Company") hereby guarantee that the information presented
in this report is authentic, accurate and complete and free of false records, misleading statements or material
omissions, and shall undertake individual and joint legal liabilities. 2. The Company's legal representative, the officer in charge of accounting, and the head of accounting
department (accounting supervisor) hereby declare that the financial information in this quarterly report is
authentic, accurate and complete.
3. Has the First Quarterly Report been audited?
□Yes ?No
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese
and other language version of public notice, they should ensure the content of both versions are the same. In the
case of discrepancy, the original version in Chinese shall prevail. I. Key Financial Data
(I) Key accounting data and financial indicators
Does the Company need to retroactively adjust or restate the accounting data of previous years? □Yes ?No
| | Current reporting period | Same period last year | Increase or decrease during the
current reporting period compared
with the same period of last year (%) | | Operating revenue (RMB) | 10,410,809,128.72 | 10,114,531,331.77 | 2.93% | | Net profit attributable to
shareholders of the listed
company (RMB) | 862,411,560.96 | 755,284,976.47 | 14.18% | | Net profit attributable to
shareholders of the listed
company after deduction of
non-recurring profits and
losses (RMB) | 838,303,551.41 | 757,542,618.01 | 10.66% | | Net cash flow from operating
activities (RMB) | -484,522,666.13 | -246,152,770.16 | -96.84% | | Basic earnings per share
(RMB/share) | 0.4929 | 0.4316 | 14.20% | | Diluted earnings per share
(RMB/share) | 0.4928 | 0.4315 | 14.21% | | Weighted average return on
equity | 4.01% | 3.99% | 0.02% | | | End of the current
reporting period | End of the last year | Increase or decrease at the end of the
current reporting period compared
with the end of the last year (%) | | Total assets (RMB) | 34,467,844,280.37 | 33,509,361,816.98 | 2.86% | | Owners' equity attributable to
shareholders of listed
companies (RMB) | 21,955,243,888.90 | 21,047,609,756.66 | 4.31% |
(II) Non-recurring profit and loss items and amounts
?Applicable □Not applicable
Unit: RMB
| Item | Amount during the current reporting period | Description | | Profit and loss on disposal of non-current assets (including
the write-off of provision for impairment of assets) | 1,521,275.31 | | | Government grants included in the current profits and
losses (except those that are closely related to the normal
business operation of the Company, comply with national
policies and regulations, are enjoyed in accordance with the
defined criteria, and have a lasting impact on the
Company's profits and losses) | 28,822,099.15 | | | Profits and losses from changes in fair value arising from
financial assets and financial liabilities held by non-
financial corporations, and profits and losses from the
disposal of financial assets and liabilities, except for the
effective hedging business related to the normal business
operation of the Company | -25,364.49 | | | Other non-operating revenue and expenses other than those
mentioned above | -1,436,525.67 | | | Minus: Amount affected by income tax | 4,281,616.36 | | | Amount affected by minority interests (after tax) | 491,858.39 | | | Total | 24,108,009.55 | -- |
Details of other profit and loss items conforming to the definition of non-recurring profits and losses
□Applicable ?Not applicable
The Company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and
losses.
An explanation of the fact that the non-recurring profit and loss items listed in the Explanatory Announcement No.1 on
Information Disclosure by Companies that Offer Securities to the Public - Non -recurring Profits and Losses are defined as
recurring profit and loss items
□Applicable ?Not applicable
The Company did not define the non-recurring profit and loss items listed in the Explanatory Announcement No.1 on Information
Disclosure by Companies that Offer Securities to the Public - Non -recurring Profits and Losses as recurring profit and loss items.
(III) Details and reasons for changes in key accounting data and financial indicators ?Applicable □Not applicable
| Items in the balance sheet | Amount at the
end of the
period | Amount at the
beginning of the
period | Percentage
change | Reasons for changes | | Notes receivable | 0.00 | 681.21 | -100.00% | Mainly attributable to the decrease in
commercial acceptance bills receivable
during the current period | | Receivables financing | 84,325.79 | 143,436.63 | -41.21% | Mainly attributable to discounting of bank
acceptance bills during the current period | | Other accounts receivable | 47,383.63 | 29,113.51 | 62.75% | Mainly attributable to an increase in
provisional payment receivable | | Short-term borrowings | 108,359.71 | 82,238.03 | 31.76% | Mainly attributable to an increase in loans
during the current period | | Advance receipts | 40.52 | 139.36 | -70.92% | Mainly attributable to a decrease in rental
received in advance | | Employee compensation
payable | 21,539.69 | 35,914.85 | -40.03% | Mainly attributable to remuneration paid
during the current period | | Non-current liabilities due
within one year | 20,941.37 | 35,934.26 | -41.72% | Mainly attributable to the payment of long-
term payables and long-term borrowings
due within one year during the current
period | | Lease liabilities | 8,300.63 | 5,669.52 | 46.41% | Mainly attributable to additional leases
during the current period | | Long-term accounts
payable | 2,480.53 | 10,725.12 | -76.87% | Mainly attributable to the transfer of
outstanding acquisition amounts to non-
current liabilities due within one year | | Other comprehensive
income | 24.80 | -4,034.15 | 100.61% | Mainly attributable to an increase in
foreign currency translation differences | | Items in the profit
statement | Amount in the
current period | Amount in the
previous period | Percentage
change | Reasons for changes | | Financial expenses | 755.50 | 2,915.08 | -74.08% | Mainly attributable to an increase in net
interest income | | Other income | 3,831.17 | 1,458.25 | 162.72% | Mainly attributable to an increase in
revenue-related government grants | | Proceeds from disposal of
assets | 152.13 | -219.99 | 169.15% | Mainly attributable to an increase in
proceeds from disposal of fixed assets | | Items in the cash flow | Amount in the | Amount in the | Percentage | Reasons for changes | | | | previous period | change | | | Net cash flow from
operating activities | -48,452.27 | -24,615.28 | -96.84% | Mainly attributable to the increase in
purchases of goods and cash paid to
employees | | Net cash flows from
investing activities | -70,737.61 | -44,005.53 | -60.75% | Mainly attributable to added investment
during the current period | | Net cash flow from
financing activities | 7,149.63 | -84,941.26 | 108.42% | Mainly attributable to the year-on-year
increase in loans during the current period |
II. Shareholder Information
(I) Total number of common shareholders, number of preferred shareholders with restored voting rights
and shareholdings of top 10 shareholders
Unit: Shares
| Total number of common shareholders
at the end of the reporting period | 93,834 | Total number of preferred shareholders with restored
voting rights at the end of the reporting period (if
any) | 0 | | | | | Shareholdings of top 10 shareholders (excluding shares lent through refinancing) | | | | | | | | Name of
shareholder | Nature of
shareholder | Shareholdi
ng ratio
(%) | Number of
shares held | Number of
shares held
with restricted
sale conditions | Pledged, marked or locked-up
status | | | | | | | | Status of shares | Quantity | | China Grand
Enterprises, INC. | Domestic non-
state-owned
legal person | 41.66% | 730,938,157.00 | 0.00 | Pledged | 147,070,000.00 | | Hangzhou Huadong
Medicine Group
Co., Ltd. | State-owned
legal person | 16.42% | 288,000,000.00 | 0.00 | Not applicable | 0.00 | | Hong Kong
Securities Clearing
Company Limited | Overseas legal
person | 2.75% | 48,286,883.00 | 0.00 | Not applicable | 0.00 | | China Securities
Finance Corporation
Limited | Domestic non-
state-owned
legal person | 1.26% | 22,186,818.00 | 0.00 | Not applicable | 0.00 | | Industrial and
Commercial Bank
of China Limited -
Zhong Ou AMC
Medical and Health
Hybrid Securities
Investment Fund | Others | 1.15% | 20,099,373.00 | 0.00 | Not applicable | 0.00 | | China Construction
Bank Corporation -
E Fund CSI 300
Medical and Health
Trading Open Index
Securities
Investment Fund | Others | 0.72% | 12,696,732.00 | 0.00 | Not applicable | 0.00 | | China Construction
Bank Corporation -
ICBC Credit Suisse
Frontier Medical
Equity Securities | Others | 0.68% | 12,000,000.00 | 0.00 | Not applicable | 0.00 | | Investment Fund | | | | | | | | National Social
Security Fund -
Portfolio 110 | Others | 0.63% | 10,983,604.00 | 0.00 | Not applicable | 0.00 | | Industrial and
Commercial Bank
of China Limited -
Huatai-PB CSI 300
Open-ended Index
Fund | Others | 0.54% | 9,494,245.00 | 0.00 | Not applicable | 0.00 | | China Life
Insurance (Group)
Company -
Traditional -
General Insurance
Products - 005L-
CT001 Shanghai | Others | 0.50% | 8,819,214.00 | 0.00 | Not applicable | 0.00 | | Shareholdings of the top 10 shareholders without restricted sales conditions | | | | | | | | Name of shareholder | Number of shares held without restricted sale
conditions | Type of shares | | | | | | | | Type of shares | Quantity | | | | | China Grand Enterprises, INC. | 730,938,157.00 | RMB-
denominated
ordinary share | 730,938,157.00 | | | | | Hangzhou Huadong Medicine Group
Co., Ltd. | 288,000,000.00 | RMB-
denominated
ordinary share | 288,000,000.00 | | | | | Hong Kong Securities Clearing
Company Limited | 48,286,883.00 | RMB-
denominated
ordinary share | 48,286,883.00 | | | | | China Securities Finance Corporation
Limited | 22,186,818.00 | RMB-
denominated
ordinary share | 22,186,818.00 | | | | | Industrial and Commercial Bank of
China Limited - Zhong Ou AMC
Medical and Health Hybrid Securities
Investment Fund | 20,099,373.00 | RMB-
denominated
ordinary share | 20,099,373.00 | | | | | China Construction Bank Corporation -
E Fund CSI 300 Medical and Health
Trading Open Index Securities
Investment Fund | 12,696,732.00 | RMB-
denominated
ordinary share | 12,696,732.00 | | | | | China Construction Bank Corporation -
ICBC Credit Suisse Frontier Medical
Equity Securities Investment Fund | 12,000,000.00 | RMB-
denominated
ordinary share | 12,000,000.00 | | | | | National Social Security Fund -
Portfolio 110 | 10,983,604.00 | RMB-
denominated
ordinary share | 10,983,604.00 | | | | | Industrial and Commercial Bank of
China Limited - Huatai-PB CSI 300
Open-ended Index Fund | 9,494,245.00 | RMB-
denominated
ordinary share | 9,494,245.00 | | | | | China Life Insurance (Group) Company
- Traditional - General Insurance
Products - 005L-CT001 Shanghai | 8,819,214.00 | RMB-
denominated
ordinary share | 8,819,214.00 | | | | | Description of affiliation or concerted action of the
above shareholders | The Company did not know whether there was any relationship among
the above shareholders, or whether they were parties acting in concert. | | | | | | | Description of the participation in securities margin
trading business of top 10 shareholders (if any) | As of the end of the current reporting period, none of the top 10 common
shareholders of the Company held shares of the Company through
securities margin trading accounts. | | | | | |
Participation in the lending of shares through refinancing business of shareholders holding more than 5% of shares, top 10
shareholders and top 10 shareholders holding tradable shares without restricted sale conditions ?Applicable □Not applicable
Unit: Shares
| Participation in the lending of shares through refinancing business of shareholders holding more than 5% of shares, top 10
shareholders and top 10 shareholders holding tradable shares without restricted sale conditions | | | | | | | | | | Name of
shareholder
(full name) | Shares held in ordinary
accounts and credit
accounts at the beginning
of the period | | Shares lent through
refinancing and not yet
returned at the
beginning of the period | | Shares held in ordinary
accounts and credit accounts
at the end of the period | | Shares lent through
refinancing and not yet
returned at the end of
the period | | | | Total
number of
shares | Proportion
in share
capital | Total
number
of shares | Proportion
in share
capital | Total
number of
shares | Proportion
in share
capital | Total
number
of shares | Proportion
in share
capital | | China Grand
Enterprises,
INC. | 730,938,157 | 41.66% | 0 | 0.00% | 730,938,157 | 41.66% | 0 | 0.00% | | Hangzhou
Huadong
Medicine
Group Co.,
Ltd. | 288,000,000 | 16.42% | 0 | 0.00% | 288,000,000 | 16.42% | 0 | 0.00% | | Hong Kong
Securities
Clearing
Company
Limited | 47,954,932 | 2.73% | 0 | 0.00% | 48,286,883 | 2.75% | 0 | 0.00% | | China
Securities
Finance
Corporation
Limited | 22,186,818 | 1.26% | 0 | 0.00% | 22,186,818 | 1.26% | 0 | 0.00% | | Industrial and
Commercial
Bank of China
Limited -
Zhong Ou
AMC Medical
and Health
Hybrid
Securities
Investment
Fund | 31,080,515 | 1.77% | 0 | 0.00% | 20,099,373 | 1.15% | 0 | 0.00% | | China
Construction
Bank
Corporation -
E Fund CSI
300 Medical
and Health
Trading Open
Index
Securities
Investment
Fund | 12,896,932 | 0.74% | 328,500 | 0.02% | 12,696,732 | 0.72% | 0 | 0.00% | | China | 19,000,000 | 1.08% | 0 | 0.00% | 12,000,000 | 0.68% | 0 | 0.00% | | Construction
Bank
Corporation -
ICBC Credit
Suisse
Frontier
Medical
Equity
Securities
Investment
Fund | | | | | | | | | | National
Social
Security Fund
- Portfolio 110 | 13,619,804 | 0.78% | 0 | 0.00% | 10,983,604 | 0.63% | 0 | 0.00% | | Industrial and
Commercial
Bank of China
Limited -
Huatai-PB
CSI 300
Open-ended
Index Fund | 6,639,145 | 0.38% | 17,500 | 0.00% | 9,494,245 | 0.54% | 4,600 | 0.00% | | China Life
Insurance
(Group)
Company -
Traditional -
General
Insurance
Products -
005L-CT001
Shanghai | 7,582,314 | 0.43% | 0 | 0.00% | 8,819,214 | 0.50% | 0 | 0.00% |
Change in top 10 shareholders and top 10 shareholders holding tradable shares without restricted sale conditions due to
lending/returning of shares through refinancing as compared to the previous period ?Applicable □Not applicable
Unit: Shares
| Changes in top 10 shareholders and top 10 shareholders holding tradable shares without restricted sale conditions due to
lending/returning of shares through refinancing as compared to the previous period | | | | | | | Name of shareholder
(full name) | Addition/with
drawal during
the current
reporting
period | Number of shares lent through
refinancing and not yet returned at the
end of the period | | Number of shares held in shareholders'
ordinary accounts and credit accounts
and shares lent through refinancing and
not yet returned at the end of the period | | | | | Total number of
shares | Proportion in share
capital | Total number of
shares | Proportion in share
capital | | Industrial and
Commercial Bank of
China Limited - Huatai-
PB CSI 300 Open-
ended Index Fund | Addition | 4,600 | 0.00% | 9,498,845 | 0.54% | | China Life Insurance
(Group) Company -
Traditional - General
Insurance Products -
005L-CT001 Shanghai | Addition | 0 | 0.00% | 8,819,214 | 0.50% | | New China Life
Insurance Co., Ltd. -
Traditional - General
Insurance Products -
018L-CT001 Shenzhen | Withdrawal | 0 | 0.00% | 6,920,836 | 0.39% | | Bank of Shanghai Co.,
Ltd. - Yinhua CSI
Innovative
Pharmaceutical Industry
Traded Open-ended
Index Securities
Investment Fund | Withdrawal | 0 | 0.00% | 7,318,298 | 0.42% |
(II) Total number of preferred shareholders and shareholding list of top 10 preferred shareholders of the
Company
□Applicable ?Not applicable
Ⅲ. Other Important Matters
?Applicable □Not applicable
(I) Overview of the Company's overall operations during the reporting period In 2024, the reform of the domestic pharmaceutical industry continued to be expanded, which, coupled with market competition, drove the intensification of the differentiation of pharmaceutical
enterprises. By focusing on the overall strategic planning and annual business objectives, the Company actively promoted the implementation of various operational management work, and achieved a good start in the first quarter. During the reporting period, the Company achieved operating income in the amount of RMB 10.411 billion, up 2.93% year-on-year; net profit attributable to parent company in the amount of RMB 862 million, up 14.18% year-on-year; net profit attributable to the parent company after deducting non-recurring profits and losses in the amount of RMB 838 million, up 10.66% year-on-year; and realized a positive growth in operating income and net profit compared with the fourth quarter of 2023. After deducting the equity incentive expenses and the profits and losses of participating and holding R&D institutions, net profit attributable to shareholders of the listed company upon deduction of non-recurring profits and
losses during the reporting period was amounted to RMB 928 million, representing an increase of 22.45% compared with the net profit attributable to shareholders of the listed company upon deduction of non-recurring profits and losses in the first quarter of 2023. During the reporting period, the overall operation of the core subsidiary Zhongmei Huadong continued to maintain a stable growth trend, achieved operating income (including CSO business) in the amount of RMB 3.399 billion, showing a year-on-year increase of 10.53%; and achieved year-on-year increase of 11.67%.
During the reporting period, the Company's pharmaceutical business segment achieved an overall operating income of RMB 6.717 billion, down 1.86% year-on-year, and a net profit of RMB 107 million, up 1.51% year-on-year. The decreasing operating income of the Company's pharmaceutical business segment was mainly affected by the higher base in the first quarter of 2023. It is expected that the pharmaceutical business segment will return to show positive growth in
the second quarter.
The Company's aesthetic medicine business continued to maintain a good growth momentum during the reporting period. Its aesthetic medicine segment realized a consolidated operating income of RMB 630 million (excluding internal offsets), representing a year-on-year increase of 25.30%. Sinclair UK, a wholly-owned subsidiary, continued to expand the global aesthetic medicine market, realized a consolidated operating income of approximately RMB 272 million during the reporting period. Due to fluctuations in demands caused by the impact of the slowdown in global macro-economic growth, it underwent a year-on-year decline of 4.40%, with the overall income reaching the operating target for the first quarter. Growth rate is expected to gradually pick up from
the second quarter. Sinclair (Shanghai), a wholly-owned subsidiary engaging in domestic aesthetic medicine, was actively expanding the domestic market. During the reporting period, it achieved operating income of RMB 257 million, representing a year-on-year increase of 22.65%, and a quarter-on-quarter increase of 13.38% compared with the fourth quarter of 2023. During the reporting period, the income of the Company's industrial microbiology business maintained a stable growth, up 23.00% year-on-year. Subsequently, along with the active expansion of the overseas market, increasing online and offline marketing promotion for the domestic animal health business and the launching of products of Hubei Magic Health, it is expected that the growth
of industrial microbiology business will accelerate.
(II) Important R&D progress of the Company during the reporting period During the reporting period, the Company accelerated its R&D efforts and continued to increase its R&D investment. The Company's R&D investment in the pharmaceutical industry (excluding equity investment) amounted to RMB 588 million during the reporting period, of which, direct R&D expenditure amounted to RMB 349 million, representing a year-on-year increase of 13.96%. The Company's innovative drugs and biosimilar business ushered in a number of important milestones. The main progress is described as follows:
1. The Company's BLA application in China for the recurrent pericarditis indication of Rilonacept (ARCALYST?) for injection, a global innovative product introduced from Kiniksa, 2. The Company's Chinese IND application for HDM1005, which is the GLP-1R/GIPR dual-target, long-acting peptide agonist product independently developed by the Company, intended for weight management among overweight or obese people and for Type 2 diabetes, was approved in March 2024. The first subject was enrolled and administered in the phase Ia clinical study in China
in March 2024. In addition, the US IND application of HDM1005 for overweight or obesity indications was approved in April 2024;
3. Chinese IND Application for HDM2005, the first ADC program that is independently developed by the Company and intended for the treatment of advanced solid tumors and hematological tumors, was submitted and accepted in March 2024; 4. In March 2024, the Company's U.S. partner announced that ELAHERE? (Mirvetuximab Soravtansine Injection), an ADC drug intended for the treatment of platinum-resistant ovarian cancer, has been converted from accelerated approval to full approval in the United States. In April
2024, the Company was approved to join the international multi-center PSOC (platinum-sensitive ovarian cancer) Phase III clinical study, to promote this product for the frontline treatment of ovarian cancer. It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, epithelial ovarian, primary peritoneal, or fallopian tube cancers with
positive folate receptor alpha (FRα) in combination with bevacizumab; 5. The NDA application for Relmapirazin Injection in China, which is an innovative drug used in conjunction with a glomerular filtration rate dynamic monitoring system, was accepted in January 2024;
6. On March 1, 2024, CARsgen's CAR-T product Zevorcabtagene Autoleucel Injection (trade name: Saikaize?, R&D code: CT053), has received notification from the National Medical Products Administration (NMPA) that it has been granted conditional approval for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent). The Company was granted the exclusive right to commercialize zevorcabtagene autoleucel in mainland China, and has set up a dedicated commercialization team. The first prescription was issued on the day when such product was approved for marketing.
In addition, the Company's generic drug registration was proceeded as planned. Tacrolimus Extended-Release Capsules with a specification of 5mg were approved by the NMPA for marketing in February 2024.
During the reporting period, the Company continued to promote the registration and implementation of key aesthetic medicine in China:
containing sodium hyaluronate for injection, successfully reached the primary study endpoint and showed good product safety data. The application for registration of this product as a Class III medical device in China has recently been accepted;
2. Two innovative botulinum toxin products under development, i.e., ATGC-110 (Type A botulinum toxin) and YY001 (Type A recombinant botulinum toxin), which were introduced by the Company in cooperation with South Korea ATGC and Chongqing Claruvis, have made significant progress respectively: the marketing application of ATGC-110 has been accepted by the Ministry of Food and Drug Safety (MFDS) of Korea. The declared indication is to improve the moderate to severe frown lines between eyebrows among adult patients. YY001 has completed the enrollment of Phase III clinical subjects in China.
(III) Other important matters
The Company held the 20th Meeting of the 10th Session of the Board of Directors on February 7, 2024, reviewed and approved the Proposal on Investment in Construction of Bio-Innovation and Intelligent Manufacturing Center Project, which agreed that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, would invest in construction of the Bio-Innovation and Intelligent Manufacturing Center Project in accordance with its own development plan and new product launch plan. The total investment amount of this project is expected to be RMB 2 billion. This project would be carried out in stages. The investment amount of Phase I is about RMB 1.188 billion (the final investment amount is subject to the actual investment expenditure of the project construction) (for details, please refer to the relevant announcements disclosed by the Company at www.cninfo.com.cn, with the Announcement No.: 2024-006).
(IV) Registration form of receptions, including research, communication, interview and other activities during the reporting period
| Reception
date | Reception
location | Receptio
n mode | Reception
object type | Reception
object | Main topics
discussed and
information
provided | Basic information
index of the survey | | January 9
and 10,
2024 | Meeting
room of the
Company | Site
survey
and
online
meeting | Institution | New China
Asset
Management,
Industrial
Securities,
Guotai Junan
Securities, etc. | Investor
communicatio
n | For details, please
refer to the Record
Sheet of Investor
Relations Activities
on January 9 and
10, 2024 published
by the Company at
https://irm.cninfo.co
m.cn/ and at
www.cninfo.com.cn. | | January 16
and 17, | Meeting
room of the | On-site
survey | Institution | Haitong
Securities, | Investor
communicatio | For details, please
refer to the Record | | 2024 | Company | | | Origin Asset
Management,
SWS MU
Fund, etc. | n | Sheet of Investor
Relations Activities
on January 16 and
17, 2024 published
by the Company at
https://irm.cninfo.co
m.cn/ and at
www.cninfo.com.cn. | | March 4,
2024 | Meeting
room of the
Company | Online
meeting | Institutions
and
individuals | Soochow
Securities,
Zhong Ou
Asset
Management,
Perseverance
Asset
Management,
etc. | Exchange
Meeting for
Launching
New Drug
Saikaize? of
Huadong
Medicine and
CARsgen
Therapeutics | For details, see the
Record Sheet of
Investor Relations
Activities on March
4, 2024, which was
published by the
Company at
https://irm.cninfo.co
m.cn/ and at
www.cninfo.com.cn. | | April 18,
2024 | Meeting
room of the
Company | Online
meeting | Institutions
and
individuals | CICC, China
Securities, TF
Securities, etc. | 2023 Annual
Performance
Exchange
Meeting of
Huadong
Medicine | For details, see the
Record Sheet of
Investor Relations
Activities on April
18, 2024, which was
published by the
Company at
https://irm.cninfo.co
m.cn/ and at
www.cninfo.com.cn. |
IV. Quarterly Financial Statements
(I) Financial statements
1. Consolidated balance sheet
Prepared by: Huadong Medicine Co., Ltd.
March 31, 2024
Unit: RMB
| Item | Closing balance | Opening balance | | Current assets: | | | | Monetary funds | 3,563,064,869.46 | 4,663,378,011.64 | | Deposit reservation for balance | | | | Lendings to banks and other financial institutions | | | | Trading financial assets | | | | Derivative financial assets | 16,409,129.45 | 16,434,493.97 | | Notes receivable | | 6,812,089.97 | | Accounts receivable | 9,677,692,232.29 | 7,455,250,690.83 | | Receivables financing | 843,257,932.30 | 1,434,366,300.69 | | Prepayments | 362,069,336.43 | 279,207,655.40 | | Premium receivable | | | | Reinsurance accounts receivable | | | | Reinsurance contract reserve receivable | | | | Other accounts receivable | 473,836,282.59 | 291,135,104.33 | | Including: Interest receivable | | | | Dividends receivable | 2,623,608.84 | 2,623,608.84 | | Financial assets purchased for resale | | | | Inventory | 4,224,074,951.91 | 4,290,214,266.03 | | Including: Data resources | | | | Contract assets | | | | Assets held for sale | | | | Non-current assets due within one year | | | | Other current assets | 51,878,760.17 | 59,881,757.08 | | Total current assets | 19,212,283,494.60 | 18,496,680,369.94 | | Non-current assets: | | | | Loans and advances issued | | | | Debt investments | | | | Other debt investments | | | | Long-term receivables | | | | Long-term equity investment | 1,529,526,141.05 | 1,535,907,809.85 | | Investment in other equity instruments | 565,223,872.68 | 565,223,872.68 | | Other non-current financial assets | | | | Investment real estate | 12,485,783.85 | 12,746,181.87 | | Fixed assets | 4,050,202,967.46 | 4,140,144,817.51 | | Works in progress | 927,713,584.81 | 913,147,212.17 | | Productive biological assets | | | | Oil and gas assets | | | | Right-of-use assets | 139,021,674.64 | 151,175,007.16 | | Intangible assets | 2,527,437,482.39 | 2,333,787,357.62 | | Including: Data resources | | | | Development expenses | 1,068,480,143.55 | 992,532,091.86 | | Including: Data resources | | | | Goodwill | 2,596,809,693.91 | 2,598,696,062.31 | | Long-term unamortized expenses | 19,291,856.38 | 20,053,854.34 | | Deferred income tax assets | 187,808,574.44 | 187,808,574.44 | | Other non-current assets | 1,631,559,010.61 | 1,561,458,605.23 | | Total non-current assets | 15,255,560,785.77 | 15,012,681,447.04 | | Total assets | 34,467,844,280.37 | 33,509,361,816.98 | | Current liabilities: | | | | Short-term borrowings | 1,083,597,089.07 | 822,380,292.37 | | Borrowings from the central bank | | | | Borrowings from other banks and other financial institutions | | | | Trading financial liabilities | | | | Derivative financial liabilities | | | | Notes payable | 1,437,934,424.82 | 1,727,420,960.30 | | Accounts payable | 4,326,094,692.22 | 4,374,832,979.95 | | Advance receipts | 405,231.33 | 1,393,551.48 | | Contract liabilities | 170,289,424.40 | 135,459,275.17 | | Expense for financial assets sold for repurchase | | | | Deposits from customers and interbank | | | | Receivings from vicariously traded securities | | | | Receivings from vicariously underwriting securities | | | | Employee compensation payable | 215,396,862.69 | 359,148,474.25 | | Taxes and dues payable | 547,143,131.41 | 489,385,055.57 | | Other accounts payable | 2,910,002,629.17 | 2,518,621,382.87 | | Including: Interests payable | | | | Dividends payable | 143,024,219.60 | 143,024,219.60 | | Fees and commissions payable | | | | Reinsurance accounts payable | | | | Liabilities held for sale | | | | Non-current liabilities due within one year | 209,413,662.46 | 359,342,623.38 | | Other current liabilities | 18,040,693.69 | 14,621,494.85 | | Total current liabilities | 10,918,317,841.26 | 10,802,606,090.19 | | Non-current liabilities: | | | | Reinsurance contract reserves | | | | Long-term borrowings | 519,383,524.08 | 520,759,460.07 | | Bonds payable | | | | Including: Preferred share | | | | Perpetual bonds | | | | Lease liabilities | 83,006,313.46 | 56,695,158.59 | | Long-term accounts payable | 24,805,289.23 | 107,251,248.59 | | Long-term employee compensation payable | | | | Estimated liabilities | 38,460,444.39 | 37,184,074.06 | | Deferred income | 167,391,739.98 | 171,056,435.34 | | Deferred income tax liabilities | 182,493,233.05 | 184,373,974.04 | | Other non-current liabilities | 46,192,650.00 | 47,170,650.00 | | Total non-current liabilities | 1,061,733,194.19 | 1,124,491,000.69 | | Total liabilities | 11,980,051,035.45 | 11,927,097,090.88 | | Owners’ equity: | | | | Share capital | 1,754,327,548.00 | 1,754,425,348.00 | | Other equity instruments | | | | Including: Preferred share | | | | Perpetual bonds | | | | Capital reserve | 2,448,599,611.00 | 2,446,313,774.82 | | Minus: Treasury stock | 82,074,369.07 | 84,519,369.07 | | Other comprehensive income | 247,990.92 | -40,341,544.18 | | Special reserves | | | | Surplus reserves | 1,277,779,972.18 | 1,277,779,972.18 | | General risk reserves | | | | Undistributed profit | 16,556,363,135.87 | 15,693,951,574.91 | | Total owners' equity attributable to the parent company | 21,955,243,888.90 | 21,047,609,756.66 | | Minority interests | 532,549,356.02 | 534,654,969.44 | | Total owners’ equity | 22,487,793,244.92 | 21,582,264,726.10 | | Total liabilities and owners’ equity | 34,467,844,280.37 | 33,509,361,816.98 |
Legal Representative: Lv Liang Officer In Charge of Accounting: Lv Liang Head of Accounting Department: Qiu Renbo （未完）
|
|
